Betamethasone Sodium Phosphate Nasal Drops
Brand names: Betnesol Drops (0.1%)
Betamethasone sodium phosphate nasal drops deliver a potent corticosteroid directly to the nasal mucosa, typically for severe nasal polyps, persistent rhinitis or marked nasal obstruction not controlled by standard sprays.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Betamethasone is a potent glucocorticoid that suppresses local mucosal inflammation and oedema, reducing polyp size and improving nasal airflow.
Prescribing in practice
- Because betamethasone is more systemically absorbed than modern intranasal steroids, prolonged or high-dose use risks systemic corticosteroid effects and adrenal suppression, so courses should be limited and supervised.
- Correct head positioning when instilling the drops is essential to reach the polyp-bearing area and improve effectiveness.
- Avoid in untreated nasal or sinus infection, and use cautiously where there is recent nasal surgery or trauma.
Monitoring
For longer or repeated courses watch for features of systemic steroid exposure and review nasal response and the need for ENT referral or surgery.
Counselling the patient
- Use the recommended head-down position so the drops reach the right area.
- Do not exceed the prescribed duration without review.
- Report visual disturbance, mood change or other steroid-related effects.
Evidence & guidelines
Intranasal corticosteroids are first-line medical therapy for nasal polyps, with betamethasone drops reserved for short, supervised courses in resistant disease.
Reference: NICE CKS Nasal Polyps; BAO-HNS Guideline for Rhinosinusitis (2016); EPOS 2020; SPC Betnesol Drops; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Adult Upper Airway Obstruction (Stridor) · DAS 2015 unanticipated difficult airway; RCEM
- Epistaxis Management · ENT-UK / NICE
- Acute Otitis Media · NICE NG91 2018
- Tonsillitis and Sore Throat · NICE NG84 2018
- Benign Paroxysmal Positional Vertigo · NICE CG124 / AAO-HNS Guidelines
- Acute Rhinosinusitis · NICE NG79 2017 / EPOS 2020